For comments or suggestion write or call: ADVERSE DRUG REACTION MONITORING CENTER*Bureau of Food and Drugs*Civic Drive, Filinvest Corporate Center Alabang, Muntinlupa City*Telephone Nos.: 807-8517 / 807-8285
To DOH Site!!!

To BFAD Site!
D O H B F A D
WELCOME TO NADRAC









NADRAC MAILING LIST
 
Please subscribe to our mailing list to receive important announcements and Signal issue to your email.
Thank you.
E-mail address:
Downloads
  ADR Report Forms
Printable Monthly Newsletter
   
  National Adverse Drug Reaction Advisory Committee, Philippines I N T R O D U C T I O N 
 

BFAD-National Adverse Drug Reaction Advisory Committee
(NADRAC)

.
W  
elcome to the new website of the National Adverse Drug Reaction Advisory Committee of the Bureau of Food and Drug. The website has been developed in aid of monitoring, reporting, collating and

analyzing reports of adverse drug reactions (ADRs) coming from all parts of the Philippines. The purpose of the Committee is NOT to criticize or castigate the prescribers. Neither does it aim to stop usage of a drug in the market. Its primary goal is to optimize the usage of pharmaceutical products and promote rational prescribing. How? By collating reports of suspected adverse drug reactions, a hypothesis can be generated and the drug further studied to quantify the true probability of its ADR. It also allows estimation of other factors that could explain, confound or precipitate the ADR. This will eventually lead to valuable information on how to use the drug optimally and properly. It will also decrease drug cost because the drug is chosen well taking into consideration the profile of the patient, the contribution of the disease to outcome and the influence of the other drugs to its safety and efficacy.

BACKGROUND OF PHARMACOVIGILANCE

The early 70s saw the inception of pharmacovigilance from the unfortunate Thalidomide accident which caused varied limb to neurologic defects among offsprings of mothers who took the drug during their pregnancies. It was a harsh and sad reminder that safety with drug use must be established as diligently as we try to prove its efficacy. However, unlike efficacy which can be tested using a comparator drug and clinical outcomes, safety is a function of the time and number of users. Moreover, there is no comparator since one does not entirely know what side effects the drug can cause. Instead, what is available are bacground incidents of the side effects.Recently, development in genetics and toxicogenetics has also uncovered the different ways that patients metabolize drugs causing different likelihood of idiosyncratic drug reactions.

The longer we use a particular drug, the greater likelihood of witnessing its adverse effects and uncovering its secondary indications and benefits. Aspirin-now an anti-platelet on top of its analgesic and antipyretic effect, cimetidine-a potential immunostimulant and COX inhibitors for Alzheimer are just some of examples of drug indications not originally included in the initial package inserts.

On the other hand, sudden cardiac arrest from the interaction of non sedating antihistamine, astemizole with the macrolide antibiotics, anemia from nifedipine, aplastic anemia from chloramphenicol are examples of unpredictable adverse effects which became apparent only during the marketing phrase of the drugs.

The Thalidomide accident also taught pharmacologists and policy makers the ineffectual consequences of banning ,withdrawing or prolonging registration of a drug from the market. First, banning a drug can only shift prescribing to another drug which may be more harmful that the banned drug. Second, hypertensive patients in Europe were already enjoying the beneficial effects of betablockers much earlier than Americans due to the delay of approval for marketing by the FDA. More importantly, drugs are limited resources whose development can run for 5 to 10 years consuming substantial amount of money and time. It is a waste of resources if a drug ‘s existence is terminated without looking at other factors that may have contributed to its adverse effects. Efficacy should always be balanced by the safety of the drug choice. Let us protect these resources. Lastly, there is no safe drug, only unsafe physicians. These are the realities that paved the way to the birth of Pharmacoepidemiology and Pharmacovigilance, disciplines which make use of the investigative tools of epidemiology to explain adverse drug reactions.

We now challenge all prescribers-- PLEASE REPORT REPORT REPORT all suspected adverse drug reactions to help optimize the use of pharmaceutical products.Morevoer, local data which is more relevant to the Filipino patients can customize therapeutic guidelines. Finally, although drug treatment for a disease may be the same across races, health seeking behaviors, patient's compliance, demography and the health delivery systems which can affect clinical outcomes can be very different.

 
Website Developed by Mr. Leopoldo VIII Mojal Chico (PCUCS4b2002) and Dr. Godofreda Dalmacion MD. Updated sy. last February 3, 2003